CZ20023518A3 - Léčivo pro inhibici růstu buněk non-solidních nádorů - Google Patents

Léčivo pro inhibici růstu buněk non-solidních nádorů Download PDF

Info

Publication number
CZ20023518A3
CZ20023518A3 CZ20023518A CZ20023518A CZ20023518A3 CZ 20023518 A3 CZ20023518 A3 CZ 20023518A3 CZ 20023518 A CZ20023518 A CZ 20023518A CZ 20023518 A CZ20023518 A CZ 20023518A CZ 20023518 A3 CZ20023518 A3 CZ 20023518A3
Authority
CZ
Czechia
Prior art keywords
vegfr
cells
antagonist
vegf
leukemia
Prior art date
Application number
CZ20023518A
Other languages
Czech (cs)
English (en)
Inventor
Larry Witte
Shahin Rafii
Original Assignee
Imclone Systems Incorporated
Cornell Research Foundation Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Incorporated, Cornell Research Foundation Inc. filed Critical Imclone Systems Incorporated
Publication of CZ20023518A3 publication Critical patent/CZ20023518A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
CZ20023518A 2000-03-31 2001-03-30 Léčivo pro inhibici růstu buněk non-solidních nádorů CZ20023518A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54077000A 2000-03-31 2000-03-31

Publications (1)

Publication Number Publication Date
CZ20023518A3 true CZ20023518A3 (cs) 2004-04-14

Family

ID=24156859

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20023518A CZ20023518A3 (cs) 2000-03-31 2001-03-30 Léčivo pro inhibici růstu buněk non-solidních nádorů

Country Status (10)

Country Link
EP (1) EP1436000A2 (ja)
JP (1) JP2004501070A (ja)
KR (1) KR20020087453A (ja)
AU (1) AU2001249736A1 (ja)
CA (1) CA2404040A1 (ja)
CZ (1) CZ20023518A3 (ja)
IL (1) IL151992A0 (ja)
RU (1) RU2002129574A (ja)
SK (1) SK15302002A3 (ja)
WO (1) WO2001074296A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
IL156306A0 (en) 2000-12-21 2004-01-04 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
US20040241160A1 (en) * 2001-07-13 2004-12-02 Yan Wu Vegfr-1 antibodies to treat breast cancer
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
BRPI0418102A (pt) 2003-12-23 2007-04-27 Pfizer derivados de quinolina
TWI571473B (zh) 2011-11-02 2017-02-21 埃派斯進有限公司 抗ｋｄｒ抗體及使用方法

Also Published As

Publication number Publication date
SK15302002A3 (sk) 2004-06-08
CA2404040A1 (en) 2001-10-11
JP2004501070A (ja) 2004-01-15
EP1436000A2 (en) 2004-07-14
KR20020087453A (ko) 2002-11-22
RU2002129574A (ru) 2004-04-20
AU2001249736A1 (en) 2001-10-15
WO2001074296A3 (en) 2004-05-06
IL151992A0 (en) 2003-04-10
WO2001074296A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
US20210220472A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
US9249220B2 (en) Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
ES2435727T3 (es) Anticuerpo contra PDGFR-alfa para uso en el tratamiento de tumores
US8933202B2 (en) AXL antibodies
KR20180133399A (ko) 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
CA2741127C (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
KR20210058811A (ko) 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
MX2010013144A (es) Anticuerpos anti-flt3.
CZ20023518A3 (cs) Léčivo pro inhibici růstu buněk non-solidních nádorů
US11365250B2 (en) Compositions and methods for cancer therapy
US20150152193A1 (en) Axl antibodies
BRPI0622074B1 (pt) Anticorpo ou fragmento de anticorpo humano isolado específico para pdgfr-alfa, polinucleotídeo e vetor de expressão